The Department of Veterans Affairs, Veterans Integrated Service Network (VISN) 7, awarded a $607.5K firm fixed-price purchase order to Cytopath Biopsy Lab Inc. (doing business as Cblpath) for thyroid molecular testing services at the Atlanta VA Medical Center in Decatur, Georgia. The contract, awarded on May 1, 2024, with a completion date of April 30, 2029, represents a sole source procurement for the company's proprietary ThyroSeq v3 Genomic Classifier, which analyzes genetic mutations in thyroid nodules to assess cancer risk and support clinical decision-making for veteran patients. No small business set-aside was utilized. The originating solicitation, issued as a Special Notice on March 19, 2024, emphasized that Cytopath Biopsy Lab Inc. is the exclusive manufacturer of the required ThyroSeq v3 technology, and the contractor's facility must maintain CLIA certification with an established history of performing thyroid molecular testing with high specificity, sensitivity, and predictive value for malignancy.
This award expands Cblpath's substantial federal contracting portfolio with the VA, which includes over 50 contract awards across multiple VISN regions since 2021. The company holds nine indefinite delivery contracts and blanket purchase agreements with the Department of Veterans Affairs, including major vehicles such as a $2.88M blanket purchase agreement with VISN 1 and a $2.25M agreement with VISN 6, through which it delivers ThyroSeq genomic testing services on an as-needed basis. All of Cblpath's federal contracts utilize firm fixed-price pricing structures, reflecting its competitive positioning as a specialized provider of molecular diagnostic laboratory services to the federal healthcare system.